Nature Medicine

Papers
(The TQCC of Nature Medicine is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Temporal dynamics in viral shedding and transmissibility of COVID-193086
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection3040
Post-acute COVID-19 syndrome2922
Antibody responses to SARS-CoV-2 in patients with COVID-192304
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections2178
Extrapulmonary manifestations of COVID-192154
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes2045
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-191978
A global survey of potential acceptance of a COVID-19 vaccine1789
An inflammatory cytokine signature predicts COVID-19 severity and survival1761
Respiratory virus shedding in exhaled breath and efficacy of face masks1593
Attributes and predictors of long COVID1548
A serological assay to detect SARS-CoV-2 seroconversion in humans1512
Age-dependent effects in the transmission and control of COVID-19 epidemics1271
A single-cell atlas of the peripheral immune response in patients with severe COVID-191212
Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy1209
Real-time tracking of self-reported symptoms to predict potential COVID-191095
Long-term cardiovascular outcomes of COVID-191017
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma817
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection810
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies761
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers715
A dynamic COVID-19 immune signature includes associations with poor prognosis711
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19676
Digital technologies in the public-health response to COVID-19673
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries650
AI in health and medicine648
Seasonal coronavirus protective immunity is short-lasting584
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies581
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation527
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies521
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries519
SARS-CoV-2 infection of the oral cavity and saliva503
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma484
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera483
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2481
Immune determinants of COVID-19 disease presentation and severity477
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals469
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong466
Determinants of COVID-19 disease severity in patients with cancer464
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial448
Targeting metastatic cancer446
Long COVID after breakthrough SARS-CoV-2 infection446
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda441
Single-cell multi-omics analysis of the immune response in COVID-19440
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination440
Looking beyond COVID-19 vaccine phase 3 trials438
Long COVID in a prospective cohort of home-isolated patients434
Understanding COVID-19 vaccine hesitancy423
Infection of bat and human intestinal organoids by SARS-CoV-2422
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study415
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein412
Human postprandial responses to food and potential for precision nutrition411
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus410
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa407
Symptoms and risk factors for long COVID in non-hospitalized adults403
Biomarkers for neurodegenerative diseases391
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine388
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK382
Intratumoral heterogeneity in cancer progression and response to immunotherapy379
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection371
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors369
Human–computer collaboration for skin cancer recognition368
If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future365
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer357
Deep learning in histopathology: the path to the clinic355
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes355
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy353
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants352
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19350
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial349
A deep learning system for differential diagnosis of skin diseases348
Four distinct trajectories of tau deposition identified in Alzheimer’s disease348
Toward personalized treatment approaches for non-small-cell lung cancer341
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension340
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination337
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study336
Disease and healthcare burden of COVID-19 in the United States334
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial333
Partial recovery of visual function in a blind patient after optogenetic therapy331
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer331
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial330
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis329
Brown adipose tissue is associated with cardiometabolic health328
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids325
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar322
Modeling COVID-19 scenarios for the United States321
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China319
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas318
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar317
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer316
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant315
Sixteen novel lineages of SARS-CoV-2 in South Africa313
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination306
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection304
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis304
Wearable sensor data and self-reported symptoms for COVID-19 detection303
Federated learning for predicting clinical outcomes in patients with COVID-19297
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination296
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial295
SARS-CoV-2 variants of concern are emerging in India292
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant291
Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle288
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors288
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial285
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells279
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial279
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England278
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries276
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial271
Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers270
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination267
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters263
Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling263
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence262
Cellular senescence and senolytics: the path to the clinic261
Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States261
A single-cell landscape of high-grade serous ovarian cancer260
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial259
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults257
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals256
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist256
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease254
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus251
Large language models in medicine248
Acute and postacute sequelae associated with SARS-CoV-2 reinfection245
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics244
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma244
Targeting the HIF2–VEGF axis in renal cell carcinoma244
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands242
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial241
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade241
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses239
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension239
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection238
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection238
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster236
A stochastic agent-based model of the SARS-CoV-2 epidemic in France235
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom235
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies230
Unexplained post-acute infection syndromes230
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin229
Microglial activation and tau propagate jointly across Braak stages228
Caring for patients with cancer in the COVID-19 era227
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures225
Long-term neurologic outcomes of COVID-19225
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer224
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals223
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy220
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps214
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern210
Vaccine development for emerging infectious diseases210
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)208
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies208
Closed-loop neuromodulation in an individual with treatment-resistant depression207
A guide to immunotherapy for COVID-19205
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade205
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring204
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial203
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19202
The distribution of cellular turnover in the human body201
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma200
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California200
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes199
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland199
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations198
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial197
Multimodal biomedical AI196
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies195
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results195
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial195
A roadmap to increase diversity in genomic studies194
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2194
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity189
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models189
Crowding and the shape of COVID-19 epidemics189
Articular cartilage regeneration by activated skeletal stem cells188
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma188
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer188
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma187
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma186
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study184
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach183
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial183
Using a real-world network to model localized COVID-19 control strategies182
Modeling shield immunity to reduce COVID-19 epidemic spread181
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial180
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk178
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2176
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma175
Global maps of travel time to healthcare facilities175
Increased global integration in the brain after psilocybin therapy for depression174
Modeling transmission of SARS-CoV-2 Omicron in China174
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology174
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial174
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease173
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors173
Delayed production of neutralizing antibodies correlates with fatal COVID-19173
COVID-19 dynamics after a national immunization program in Israel172
Predicting conversion to wet age-related macular degeneration using deep learning170
Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes170
A correlate of protection for SARS-CoV-2 vaccines is urgently needed167
Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis167
Reporting guidelines for human microbiome research: the STORMS checklist167
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland166
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1165
Developing specific reporting guidelines for diagnostic accuracy studies assessing AI interventions: The STARD-AI Steering Group162
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial161
Prediction of mortality from 12-lead electrocardiogram voltage data using a deep neural network161
Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes161
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors160
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease160
Targeting the gut and tumor microbiota in cancer159
Misinformation: susceptibility, spread, and interventions to immunize the public159
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial158
COVID-19 and resilience of healthcare systems in ten countries157
COVID-19 in Africa: the spread and response157
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis157
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes156
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer156
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers156
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy156
Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium154
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial154
The landscape of mRNA nanomedicine154
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma154
Wearable-device-measured physical activity and future health risk153
An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy151
Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial151
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial149
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021149
Colibactin DNA-damage signature indicates mutational impact in colorectal cancer149
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis148
An algorithmic approach to reducing unexplained pain disparities in underserved populations144
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge143
Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial143
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis143
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial142
Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice142
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial139
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma139
Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae138
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma138
Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19137
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines137
Myocardial infarction accelerates breast cancer via innate immune reprogramming135
Redefining critical illness135
AI in medicine must be explainable135
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis134
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor134
0.050179004669189